TY  - JOUR
AU  - Jungwirth, Gerhard
AU  - Cao, Junguo
AU  - Pan, Yimin
AU  - Warta, Rolf
AU  - Lotsch, Catharina
AU  - Moustafa, Mahmoud
AU  - Knoll, Maximilian
AU  - Yu, Tao
AU  - Braun, Viktor
AU  - Jassowicz, Lena
AU  - Trong, Philip Dao
AU  - Wang, Zhenlin
AU  - Younsi, Alexander
AU  - Scherer, Moritz
AU  - Bendszus, Martin
AU  - Krieg, Sandro M
AU  - von Deimling, Andreas
AU  - Debus, Juergen
AU  - Abdollahi, Amir
AU  - Unterberg, Andreas
AU  - Sahm, Felix
AU  - Herold-Mende, Christel
TI  - Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat.
JO  - Science translational medicine
VL  - 18
IS  - 839
SN  - 1946-6234
CY  - Washington, DC
PB  - AAAS
M1  - DKFZ-2026-00519
SP  - eaea3115
PY  - 2026
AB  - Managing aggressive meningiomas remains challenging because of limited treatment options besides surgical tumor removal and radiotherapy. To increase the repertoire of promising therapies for aggressive meningiomas, we established a multistep drug screening workflow, focusing on targetable genes obtained from transcriptome data of highly aggressive grade 3 meningiomas. In vitro screening of 107 targeted drugs identified nine effective inhibitors. To study these drugs in a more natural environment, we established a standardized patient-derived tumor organoid (TO) model preserving accurately the original tissue's genotype and phenotype. Individual drug responses were assessed in TOs from 60 meningioma cases characterized at the molecular level. In particular, the US Food and Drug Administration-approved epigenetic drug panobinostat demonstrated high antimeningioma efficacy in 70
LB  - PUB:(DE-HGF)16
C6  - pmid:41779868
DO  - DOI:10.1126/scitranslmed.aea3115
UR  - https://inrepo02.dkfz.de/record/310296
ER  -